Bone Marrow Transplantation in Hematologic Malignancies
- 15 February 1987
- journal article
- research article
- Published by Taylor & Francis in Hospital Practice
- Vol. 22 (2) , 77-91
- https://doi.org/10.1080/21548331.1987.11707674
Abstract
Marrow toxicity from chemotherapy or radiotherapy may be overcome by reconstituting the patient's hematopoietic capacity. In practice, allogeneic marrow transplantation has largely been limited to the leukemias. The article reviews clinical experience, emphasizing results with grafts, as well as major problems—relapse, GVHD, infection, and donor matching and availability.Keywords
This publication has 8 references indexed in Scilit:
- Cytomegalovirus Immune Globulin and Seronegative Blood Products to Prevent Primary Cytomegalovirus Infection after Marrow TransplantationNew England Journal of Medicine, 1986
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.Journal of Clinical Oncology, 1985
- Marrow Transplantation from Related Donors Other Than HLA-Identical SiblingsNew England Journal of Medicine, 1985
- Treatment of Acute Myelogenous LeukemiaAnnals of Internal Medicine, 1985
- Bone Marrow Transplantation or Chemotherapy After Remission Induction for Adults with Acute Nonlymphoblastic LeukemiaAnnals of Internal Medicine, 1984
- Allogeneic bone marrow transplantation for patients with acute lymphoblastic leukemiaBlood, 1983
- A Comparison of Marrow Transplantation with Chemotherapy for Children with Acute Lymphoblastic Leukemia in Second or Subsequent RemissionNew England Journal of Medicine, 1981